We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.
Introduction
The oligometastatic state, typically defined as ≤5 sites of distant disease, is a potentially curable form of prostate cancer (PCa). 1 In our clinical practice, hybrid positron emission tomography/computed tomography (PET/CT) with the 18 F-labeled small-molecule prostate-specific membrane antigen (PSMA) inhibitor 18 F-DCFPyL, is often used to assist in staging men with potentially oligometastatic PCa. This imaging test is available at our center through several clinical trials. For patients imaged with 18 F-DCFPyL, we routinely employ the PSMA reporting and data system (PSMA-RADS) version 1.0 standardized framework to describe the likelihood of the presence of PCa at a given anatomic location. 2 This five-point scoring system allows radiologists to communicate diagnostic confidence and follow-up recommendations to referring clinicians.
Herein, we present a case report of a 60-year-old man with newly diagnosed oligometastatic PCa in which the PSMA-RADS reporting framework was used to guide patient care.
Case presentation
A 60-year-old man presented with a serum prostate specific antigen (PSA) level of 8.24 ng/mL and cT2a digital rectal examination. The patient's history was significant for a prior poorly tolerated prostate biopsy that had demonstrated Grade Group 1 prostatic adenocarcinoma with a subsequent plan for active surveillance. The patient had, however, been lost to follow-up. When he re-presented, he underwent magnetic resonance imaging (MRI) that demonstrated extraprostatic extension and possible perirectal and obturator lymph node metastases. A repeat prostate biopsy showed progression to Grade Group 2 prostate cancer. The findings on MRI prompted a contast-enhanced CT that demonstrated indeterminate perirectal and mesenteric lymph nodes as well as a mixed lucent and sclerotic lesion in the right iliac bone. The patient also underwent a 99m Tc-methylene diphosphonate bone scan which was negative for evidence of osseous metastases. Due to the potential for metastatic disease, a PSMA-targeted 18 FDCFPyL PET/CT scan was obtained on a clinical trial evaluating the impact of PSMA-targeted PET on PCa patient management (ClinicalTrials.gov NCT02825875).
18 F-DCFPyL-avid lesions included regional lymph nodes (PSMA-RADS-4), distant lymph nodes (PSMA-RADS-3A and −4; Fig. 1 ) and an osseous iliac lesion (PSMA-RADS-3B; Fig. 2 ). Additional foci of radiotracer uptake included the prostate gland (no PSMA-RADS score assigned) and a thyroid nodule (PSMA-RADS-3C). The patient's findings on the PSMA scan are summarized in Table 1 . 
T
In accordance with recommendations from the PSMA-RADS system, 2 the patient's iliac bone lesion merited further work-up in the context of a patient possibly being offered metastasis-directed therapy. Thus, the patient underwent a subsequent tumor protocol contrast enhanced MRI (which utilized a different protocol and different field-ofview relative to his prior prostate MRI), which showed a lack of diffusion restriction as well as definitive signal dropout on out-of-phase imaging indicating fat within the presumed lesion, definitive for a benign lesion and most suggestive of a hemangioma (PSMA-RADS-1B, Fig. 2 ). Additionally, uptake in a the patient's thyroid nodule was suspicious for a non-prostate malignancy (PSMA-RADS-3C), although it was recommended that further work-up be deferred until therapy for the patient's PCa had been completed. Based on the findings of the 18 F-DCFPyL scan that was further informed by the MRI, that patient was staged as having oligometastatic cT1N1M1a PCa. The patient was in turn offered several treatment options for his remaining radiotracer-avid lesions: standard of care therapy (androgen deprivation therapy alone OR androgen deprivation therapy + chemotherapy), or a clinical trial designed to provide definitive therapy to men with oligometastatic PCa (ClinicalTrials.gov NCT02716974). The patient opted for definitive therapy and he was treated with chemohormonal therapy with docetaxel, leuprolide, and abiraterone, with a plan to undergo subsequent cytoreductive prostatectomy followed by adjuvant radiation therapy, and then focused radiation to oligometastatic lesions outside of the pelvic radiation field. Synchronous androgen deprivation therapy was started with a planned duration of one year.
Discussion
This case report illustrates the use of the PSMA-RADS reporting framework to facilitate the metastatic work-up, and to establish a treatment plan, in a man with newly diagnosed oligometastatic PCa.
PSMA-targeted PET scans take advantage of the overexpression of PSMA on prostate cancer cells to increase the overall diagnostic performance of PCa imaging. However PSMA may be overexpressed in tissues other than PCa, 3 impacting on the ability to interpret results of a PSMA-targeted PET scan. Overall, PSMA-targeted PET scans are believed to have very high sensitivity and specificity, 4 although there are interpretive pitfalls that imaging specialists and referring clinicians should be aware of. 5 PSMA-RADS facilitates the interpretation of these imaging studies by categorizing equivocal lesions and providing recommendations for further noninvasive advanced imaging work-up. As shown in this case, a standardized reporting framework such as PSMA-RADS can contribute substantially to decision-making in PCa patients with a limited amount of disease who are undergoing focal therapy. PSMA-RADS designations allowed for a diagnosis of oligometastatic disease, and a plan to target the sites of metastasis (PSMA-RADS-4 lesions) while also avoiding overtreatment of a radiotracer avid iliac bone lesion (PSMA-RADS-3B) which was found on follow-up MRI to be a benign lesion. Additionally, the PSMA-RADS system drew attention to thyroid nodule (PSMA-RADS-3C) that potential represents a non-prostate malignancy that will require work-up after the patient's PCa is treated.
Conclusion
This case report delineates how PSMA-RADS may be used to guide the work-up and treatment plan of PSMA avid lesions in patients with oligometastatic PCa. PSMA-RADS provides diagnostic confidence and recommendations for further work-up as needed. PSMA-RADS enables the clinician to understand the relevancy of the radiographic findings and to assimilate them into their clinical decision-making.
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M.G.P. is a co-inventor on a U.S. patent covering PSMA-RADS-3A -Equivocal uptake in soft tissue sites in a typical distribution for PCa Lymph nodes will be followed serially as per usual imaging follow-up, i.e, every 6 months.
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Mild radiotracer uptake in a posterior right iliac bone lesion. PSMA-RADS-3B -Equivocal uptake in a bone lesion not definitive but also not atypical for PCa on anatomic imaging
Obtained MRI tumor protocol -PSMA-RADS-3B lesion is definitively benign, therefore it is reassigned to PSMA-RADS-1B (a benign lesion with radiotracer uptake).
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Large left predominantly substernal thyroid nodule with radiotracer uptake.
PSMA-RADS-3C -Equivocal uptake in a site highly atypical of all but advanced stages of PCa
Patient will have thyroid ultrasound and be considered for ultrasound-guided biopsy after completing PCa therapy.
5
Heterogeneous radiotracer uptake throughout much of the prostate, most focally in the base and mid of the left side of the gland.
No score assigned ePSMA-RADS score is not assigned to primary disease Prostate has biopsy-proven PCa. Plan to offer prostatectomy following neoadjuvant therapy PCa: prostate cancer.
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